Kerstin Port

Hannover, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Quality of life improves during antiviral therapy with bulevirtide.

Quality of life improves during antiviral therapy with bulevirtide.

Journal: Zeitschrift fur Gastroenterologie

Published: September 11, 2025

TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.

TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.

Journal: Hepatology (Baltimore, Md.)

Published: August 21, 2024

Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.

Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.

Journal: Journal of viral hepatitis

Published: June 03, 2024

Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples.

Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples.

Journal: Hepatology (Baltimore, Md.)

Published: May 21, 2024

Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.

Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.

Journal: JHEP reports : innovation in hepatology

Published: December 29, 2023

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.

Journal: Alimentary pharmacology & therapeutics

Published: November 03, 2023

Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites.

Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites.

Journal: JAMA network open

Published: July 06, 2023

Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.

Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 23, 2023

Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.

Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.

Journal: Journal of viral hepatitis

Published: December 21, 2022

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: December 16, 2022

Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.

Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.

Journal: JHEP reports : innovation in hepatology

Published: November 06, 2022

Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.

Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.

Journal: Journal of viral hepatitis

Published: October 21, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026